Gastrointestinal Célula tumore targeting medicamento Avapritinib (Avapriny, Ayvakit: GRN-CCLXXXV) by USFDA probatus est in January 285th, 9. Quod duo lustra medicamento significant, exiit in opus ad curatio in patientibus adulta resection sive habentem platelet propriae incrementum factor metastatic SUMMA alpha (PDGFRA) XVIII mutationem exon (including PDGFRA D2020V mutationem), et quattuor recta, aut non-chirurgicam metastatic SUMMA adulta aegris.
Orr tam excelsum quod LXXXVI%, novas spes ut Avapritinib brings cum aegris tumores gastrointestinal Célula
MMXIX In November, in anno foederis nota TEXTUS qui de Societate Scandinavica (CTOS) nuntiatum eventus in NAUTA pars avapritinib et orci in die iudicii accepto aegris PDGFRA Exon XVIII mutationum et quarta linea, Summa.
1. background Research
Ut Decembris XVI, MMXVIII, summa CXXI-quarta linea et super aegris (maxime LOCULUS mutationes taceam) et cum aegris XLIII SUMMA PDGFRA Exon XVIII mutationes scripti. Iudicium curiosissime rimabatur, ut iudicium initiali, dose of "CD mg cotidie simul oris," ac postea sub ius iudiciumque suum consectetuer commendatur, ut "cum CCC mg cotidie oris" ex toxicity. Et accepit Avapritinib patientes estote ad progressum aut morbo acceptus toxicity.
2. notitia operationes efficaciam
For patients with PDGFRA exon 18 mutation, there were 3 cases of complete remission (OR) and 34 cases of partial remission (PR), and the objective response rate (ORR) was 86%. The median duration of response (DOR) and median progression-free survival (PFS) were not reached. As of the data cut-off date (median follow-up time was 10.9 months), 78% of patients still responded.
CXI De SUMMA cum aegris aut diatessaron superius versus, I completum cum tempore, cum XXIII partiali remissione, est XXII% Orr, responsio tempus mediana autem 111 mensibus, 1 mensibus medius fui PFS, et mediana sequi-sursum erat tempus 23. mensis.
Secundum incolumem, adversos casus (aes) plerumque gradus I, II atque communia nausea labore anemia ventris vomitus etc. ≥ II AE-related gradus 1-2%, anemia, lassitudine, low Phosphaemia, hyperbilirubinemia, neutropenia et a foria. X% de patientibus curatio cessare erogari ex actis curatio aes.
3. C. pretii
Avapritinib is the first precision therapy approved for GIST patients with PDGFRA exon 18 mutation. It is an oral, potent and selective KIT and PDGFRα inhibitor. Avapritinib has shown extensive inhibition in gastro stromal tumores (GIST) with KIT and PDGFRα mutations, including the D842V mutation of the PDGFRα gene and other primary or secondary resistance mutations.
XVIII-cincinno Keyless PDGFRA exon mutant SUMMA
Gastrointestinal stromal tuberculum (GIST) is a rare mesenchymal tissue tumor, accounting for 0.1% to 3% of all gastrointestinal malignant tumors, with an incidence of 1 to 1.5 / 10 million. In people with gastro stromal tumores, the most common sites are the stomach and small intestine, but they may also be found anywhere in or near the gastrointestinal tract. If the tumor cannot be completely removed by surgery or the tumor has metastasized, targeted therapy is a standard treatment.
Currently, usque ad LXXXV% of unus ex duobus gene mutationes PDGFRA SUMMA in secretiori parte natium et KIT. Hae mutationes ducunt ad abnormal LOCULUS productio et PDGFRA proteins, quas eiciam cancer. Servo plerumque binis verti possit per actionem imatinib aliaque medicamenta obstantia dapibus. Sed mutationem PDGFRA Exon XVIII valde specialis est, mutat figura ad PDGFRA de dapibus, ita ne ad hoc medicamento ex binding. Nam PDGFR [exon XVIII] mutationem, prior "clavis" Non idoneus sit «cincinno".
Avapritinib selectively et medetur percutit PDGFRA LOCULUS proteins. Elit in studiis et venefici poterit impedire actionem in omnibus tentari mutant PDGFRA servo amet turpis.
Quia probatus gastrointestinal medicinae quattuor currently Célula secretiori parte natium: Avapritinib, imatinib, sunitinib et rifaginib. Avapritinib solum obligatus ad specifica dicitur kinases mutant enzymes (rubrum circulos), in editioribus cellulis, cum pede solveris similis ad magis kinases. Image: Cell Signalling Technology.
| Targeted medicamento approbatae pro gastrointestinal Célula tumore (SUMMA) | Aliae indices cancer | domesticis album |
| Gleevec | Imatinib | Acuti lymphocytic leukemia (Philadelphia chromosome positive), chronic eosinophilic leukemia, Philadelphia chromosome positive chronic myeloid leukemia, dermatofibrosarcoma protuberans, myeloproliferative tumor | Et enumerantur includitur in medicinae assecurationis |
| Regorafenib | Stivarga | Liver cancer, colorectal cancer | Et enumerantur includitur in medicinae assecurationis |
| Sutent | Sunitinib | Xixianai, ren cancer | Et enumerantur includitur in medicinae assecurationis |
| Avapritinib (Ayvakit) | nihil | audio |
Alii progressus investigationis in secretiori parte natium gastrointestinal Célula
Ripretinib
Ripretinib is a type II kinase inhibitor that can widely inhibit the activation loop mutations in KIT and PDGFRA. It is a kinase inhibitor with a “switch control” function, which can activate the activation loop (or activate the “switch”) into The active conformation, in turn, inhibits all tested KIT and PDGFRA mutants. Ripretinib’s effectiveness in preclinical cancer models and initial clinical trials also validated that Ripretinib can inhibit the universal KIT mutation in patients with drug-resistant GIST.
Data ex studio Phase III (INVICTUS) ostendit quod aegros accepto Ripretinib LXXXV% habebat mortis vel minus periculum ex tumore progressum comparari placebo, cum medianus of OS 85 mensibus, 15.1 mensibus in Placebo et coetus. SUMMA late fourth, an linea super brings duplex curatio beneficia Dei PFS et OS, ostendit bonum tolerability et Ripretinib.
Larotrectnib
Mundi primus targeted medicamento, ut non distinguere tumore fontibus pro initialis curatio, Vitrakvi ® (larotrectinib, inferius ad ut larotinib), has been probatus per global tumore civitatis quod erat probatus pro venalicium in November MMXVIII doctores et aegris qui duxit novum ut opes et electiones.
The biggest attraction of the drug is that it is a new anti-cancer drug that targets specific gene mutations but not specific cancer types. The NTRK gene fusion solid tumors that it can treat include 17 types of cancers including breast cancer, colorectal cancer, lung cancer, and glandulae cancer, and can be used for both adults and children. NTRK gene fusion exists in 0.7% ~ 3.6% of digestive tract tumors.
Therefore, if you do a genetic test, you can first see if there are any mutations that may bring a miracle of survival, you can call the medical department of the Global Oncologist Network to interpret the report.
I believe that with the advent of more and more targeted drugs, patients with gastrointestinal stroma
l tumores plus bene curationis habere et beneficia longiora superesse. Opto praeterea haec medicamenta quam primum in Sinis recenseri posse et in assecurationis medicae ad plurium utilitatem aegrorum includi.
